{"id":"grazaoprevir-elbasavir","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Grazoprevir is a direct-acting antiviral (DAA) that targets the NS3/4A serine protease essential for HCV polyprotein processing. Elbasavir targets the NS5A protein, which is critical for viral RNA replication and virion assembly. Together, this fixed-dose combination provides dual inhibition of key HCV enzymes, achieving high cure rates across multiple genotypes.","oneSentence":"Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:50.939Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotypes 1-6"}]},"trialDetails":[{"nctId":"NCT03037151","phase":"PHASE4","title":"Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV","status":"UNKNOWN","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2018-08-01","conditions":"Compensated Cirrhosis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Grazaoprevir/Elbasavir","genericName":"Grazaoprevir/Elbasavir","companyName":"The HIV Netherlands Australia Thailand Research Collaboration","companyId":"the-hiv-netherlands-australia-thailand-research-collaboration","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, genotypes 1-6.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}